middle.news
OncoSil adds FDA approval to 45.8% revenue growth as U.S. launch approaches
9:17am on Friday 30th of October, 2026 AEDT
•
Medical Technology
Read Story
OncoSil adds FDA approval to 45.8% revenue growth as U.S. launch approaches
9:17am on Friday 30th of October, 2026 AEDT
Key Points
45.8% year-on-year Q1 FY27 sales revenue growth
FDA HDE approval for distal cholangiocarcinoma in the United States
A$5.6 million raised from three major institutional shareholders
Initial U.S. distribution limited to five academic centres and 30 patients
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Oncosil Medical (ASX:OSL)
OPEN ARTICLE